🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

APOBEC3A (RNA-editing enzyme) may be key player in TKI resistance. Great talk by Hideko Isozaki MassGeneral Medicine on role of APOBEC3A in drug-tolerant persistent state, & inducing both early & late resistance to TKIs #AACR22 #LCSM

Today in Nature - lung cancer targeted therapies can induce APOBEC3A, which drives evolution of acquired drug resistance. Terrific team effort led by Hata and Lawrence groups in collaboration with Zosia Piotrowska Lecia Sequist, MD, MPH JessicaJLinMD Justin Gainor nature.com/articles/s4158…

Nature research paper: Therapy-induced APOBEC3A drives evolution of persistent cancer cells go.nature.com/3XDMioS

We’re delighted to share our new paper, “Therapy-induced APOBEC3A drives evolution of persistent cancer cells”! Thanks to all of you who have supported this project! Lung Cancer Research Foundation LUNGSTRONG Mass General Cancer Center nature.com/articles/s4158…

【科研費「帰国発展研究」の公募開始】 海外の研究機関等において優れた研究実績を持つ研究者が、日本に帰国後すぐに研究を開始できるよう支援する科研費「帰国発展研究」の公募がスタート。 応募額は5000万円以下、研究期間は3年以内です（〆9/19）。 jsps.go.jp/j-grantsinaid/…

今日はMITの卒業式でした。モデルナ創業者のAfeyan氏から我々への祝辞。ミッション・インポシブルを可能にするには 1. Imagine: 想像から創造が始まる 2. Innovate: 道理にかなったことをするな。勇気を持って跳躍せよ 3. Immigrate: 地図なき道を歩め。不確実こそがチャンス youtube.com/watch?v=Uw3Q6v…

Now online for #ESMO24: NVL-655 Is a Selective & Brain-Penetrant Inhibitor of Diverse #ALK Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Joshua Horan, Anupong Tangpeerachaikul, et al. bit.ly/3MJtzUs JessicaJLinMD Henry Pelish Alexander Drilon MD

We are pleased to share this article out today in Cancer Discovery on the preclinical development and proof-of-concept clinical activity of NVL-655 ✅4th-generation, #ALK-selective TKI ✅CNS-penetrant ✅Broad coverage of ALK fusions and mutations, including lorlatinib-refractory compound

📚We're pleased to announce our new manuscript published in Cancer Discovery characterizing NVL-655 and detailing our approach to targeting #ALK. Thank you to our preclinical and clinical collaborators! investors.nuvalent.com/2024-09-13-Nuv…

Despite progress, advanced ALK+ lung cancer almost always recurs. By deeply exploring the biology of cancer cells that resist treatment, the new PoweRD 2 Cure ALK+ Lung Cancer TeamLab aims to bend the survival curve for patients - JessicaJLinMD #RadicalCollaboration

Announcing this year's class of LCRF research grantees! LCRF's 2024 Scientific Grant Program is funding $3.55 million in new #LungCancer research, the largest single-year investment in its history. Read more: LCRF.org/2024grants

Very nice review on HER3 targeting by Helena Yu and colleagues. A bispecific HER3xHER2 mAb was recently approved in thoracic oncology. However, despite many strategies studied to date, only anti-HER3 ADCs have shown benefit in breast oncology to date. nature.com/articles/s4157…

SAVANNAH (Ph 2): Savo + Osi EGFRm-resist NSCLC w/MET overexp (IHC90+) and/or ampl (FISH10+)~1/3 resist pts. ORR 55%, DoR 9.9, PFS 7.5 (BICR). vs MARIPOSA-2 (Ph3 Ami+ChT): ORR 53%, DoR 6.9, PFS 6.3 mo. Ph 3 SAFFRON ongoing #ESMOAmbassadors #ELCC25 ESMO - Eur. Oncology

Optimal first L TX for EGFR-mutated mNSCLC? 1. Tagrisso alone for most patients. 2. Tagrisso plus chemo for high-risk patients (brain/liver mets or large size) 3. Amivantamab: Ab EGFR and MET. Lazertinib: EGFR TK Don’t forget: SABR plus Tagrisso for oligomets or oligoprogression

Trastuzumab deruxtecan（T-DXd）の細胞外ペイロード放出と免疫調節機能が鍵 T-DXdの有効性を理解する上でとても重要な論文になると思います。 nature.com/articles/s4146…

It was great to connect with my Japanese colleague on the final day of #AACR25 ! Exciting to exchange ideas on our complementary approaches to tackling NSCLC! Toshio Fujino

Five years into the CROWN study, this follow-up shows that #lorlatinib efficacy and safety in the Asian subgroup continue to be consistent with the overall population, according to Wu et al. 🔗 Read more: bit.ly/43CSWzf